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The complexity of genomic aberrations in most human tumors hampers delineation of the 
genes that drive the tumorigenic process. In this issue of Cell, Kim et al. (2006) and Zender 
et al. (2006) demonstrate that cognate mouse tumor models recapitulate these genetic 
alterations with unexpected fidelity. These results indicate that cross-species genomic 
analysis is a powerful strategy to identify the responsible genes and assess their oncogenic 
capacity in the appropriate genetic context.Chromosomal  aberrations  recur-
rently contribute to malignant trans-
formation.  Typically,  deleted  or 
amplified  genomic  regions  cover 
large  (rather than focal) areas,  thus 
slowing  down  the  identification  of 
the  specific  genes  driving  tumori-
genesis. In two papers published in 
this  issue of Cell  (Kim et  al.,  2006; 
Zender  et  al.,  2006),  integrative 
cross-species  analysis  was  used 
to narrow down the number of can-
didate  oncogenes  within  amplified 
DNA  segments  (amplicons).  This 
approach  illustrates  the  power  of 
genome-wide  comparison  of  cog-
nate mouse and human  tumors,  as 
it  identified genes  found  in  regions 
commonly amplified in both species 
(Figure 1).
To  study  the  genes  involved  in 




ative  Genome  Hybridization  (CGH, 
which  measures  DNA  copy-num-
ber  differences  between  genomes) 
showed  that  these  cell  lines,  rela-
tive  to  their  parental  counterparts, 
shared  an  amplified  region  of  850 
kb on chromosome 13 encompass-
ing  eight  genes.  A  region  of  much 
larger  size,  syntenic  (preserved 
as  “blocks”  of  genes  across  spe-
cies)  with  the  amplified  region  in 
the  mouse,  is  frequently  observed 
in  human  melanoma.  This  ampli-
con  is more predominantly present 
in  metastatic  variants,  suggesting 
that it might harbor a gene contrib-
uting  to  the metastatic  potential  of 
melanoma.  Expression  analysis  in evier Inc.murine melanomas showed that one 
gene,  NEDD9,  was  the  most  likely 
candidate  to  enhance  metastasis. 
Subsequent analyses of NEDD9 lev-
els  in  human  melanoma  indicated 
significant  upregulation, with  levels 






and  human  cells.  Interestingly,  the 
metastatic potential of NEDD9 could 
be  abrogated  by  knocking  down 
focal adhesion kinase (FAK ), a gene 
previously  implicated  in  invasive 
growth  (Hess  et  al.,  2005).  NEDD9 
and  FAK  appear  to  colocalize  in 
focal  contacts,  which  result  from 
NEDD9  overexpression.  Therefore, 
this study not only identified a gene 











provides  a  selective  advantage  to 
primary  tumors  as  well.  In  keep-
ing with this, the authors observed 




represents  a  frequently  occurring 
phenomenon  contributing  to  both 
tumor initiation and progression, as 
previously  proposed  by  Bernards 
and Weinberg (2002). Indeed, over-
expression  of  NEDD9  stimulated 






acts  in  a  context-dependent  fash-
ion.  Notably,  it  would  have  been 
impossible  to  reach  these  conclu-
sions  so  rapidly without  the  aid  of 
this mouse model.
A second paper, by Zender et al. (2006),  published  in  this  issue  of 
Cell describes a new mouse model 
for  liver  cancer  that  permits  the 
identification  of  genes  contribut-
ing  to  hepatocellular  carcinomas 
(HCCs).  The  authors  established 
hepatoblast  cultures  allowing  in 
vitro genetic manipulation. As HCCs 
almost  invariably  harbor  inactivat-
ing  mutations  in  p53,  the  authors 
infected cultured hepatoblasts from 
p53-deficient  embryos  with  the 
oncogenes c-myc, Akt, or H-RasV12. 
Engraftment of these cells into mice 
resulted  in  liver  tumors,  albeit  with 





genes  that  might  contribute  to  the 
tumor  phenotype  were  identified. 
In  Akt-induced  tumors,  no  focal 
genomic  alterations  smaller  than  5 
Mb were  found.  H-Ras-transduced 
hepatoblasts  gave  rise  to  tumors 
with,  in  one  case,  a  focal  ampli-
fication  of  c-myc  and,  in  another, 
of  Rnf19.  Although  Rfn19  has  not 
been linked to tumorigenesis, c-myc 
alterations  are  common  in  human 
HCC.  ROMA  of  HCCs  induced  by Cell 125, Joverexpression  of  c-Myc  revealed 
a  small  amplicon  on  mouse  chro-




cancers.  The  cross-species  com-
parison  limited  the  number  of  can-
didate  genes  in  the  region.  Most 
genes  encoded  by  the  amplicon, 
including a number of matrix metal-
loproteinases,  could  be  excluded 
as  candidates  because  they  were 
not consistently overexpressed. The 
remainder  of  the  genes  could  thus 
be  responsible  for  the  phenotypic 





sis,  and  Yap  (Yagi  et  al.,  1999),  a 
Src-interacting  protein,  appeared 
overexpressed  in  all  murine  and 
human amplicon-containing tumors 
analyzed. Their contribution to HCC 
was  subsequently  evaluated  in  the 
versatile  hepatoblast  graft  model 
using  combinations  of  retroviral 
vectors  encoding  c-Myc,  cIAP1, 
and Yap. cIAP1 overexpression sig-
nificantly  enhanced  tumor  growth, une 30, 2006 ©2006 Elsevier Inc.  1231
but  only  when  c-Myc  was  overex-
pressed. cIAP1 conferred no growth 
advantage in combination with either 
H-Ras  or  Akt,  illustrating  that  the 
oncogenicity  of  cIAP1 was  context 
dependent. Yap acts to enhance the 
efficiency  of  Runx  and  TEAD/TEF 
transcription  factors.  It  can  also 
potentiate  apoptosis,  an  activity 
that seems hard to reconcile with an 






a  function  of  its  genetic  context. 
Downregulation  of  Yap  by  short-
hairpin  RNAs  (shRNAs)  resulted  in 
reduced cyclin E levels and impaired 
progression  of  the  murine  tumor 
cells.  It  will  be  interesting  to  learn 
whether  cIAP1/Yap  depletion  has 
a similar effect on the tumorigenic-
ity of human liver cancer cells. One 
often  assumes  that  single  onco-
genes  within  amplicons  bear  most 
if  not  all  of  the  tumorigenic  activ-
ity,  with  neighboring  genes  merely 
representing passengers. Strikingly, 
the authors found that coexpression 
of  c-Myc with  both  cIAP1  and  Yap 
resulted in synergistic stimulation of 
tumor growth.
These  studies  highlight  the 
power of  integrative,  cross-species 




genomic  and  expression  analyses. 
Although  the  usefulness  of  cross-
species  sequence  comparisons  is 
undisputed,  there  has  been  skep-
ticism  about  the  added  value  of 
comparing  genomic  aberrations  in 
tumors  of  different  species.  High-
resolution  CGH  analyses,  however, 
have  revealed  a  striking  concor-
dance  of  chromosomal  gains  and 
losses in syntenic regions of tumors 
in mice and humans, indicating that 
the  development  of  these  tumors 




conferring  oncogenicity  because 1232  Cell 125, June 30, 2006 ©2006 Elsmore amplicons can be scored and 
because alignment of the amplicons 




ing  their  consistent  expression  in 
both  mouse  and  human  tumors, 
thereby  creating  a  biological  sieve 




surprisingly,  have  uncovered  rela-
tively  few  cancer-associated muta-
tions so far (Davies et al., 2002).
Second,  both  studies  discussed 
here  exemplify  the  influence  of  the 
genetic context on oncogene  func-
tion.  Specifically,  NEDD9  exerts  its 
pro-oncogenic  effect  in  Ink4a/Arf-














the  decision  of  which  genes  we 
select  for  targeted  inhibition.  One 
might imagine that, for specific gene 







two  genes,  cIAP1  and  Yap—coop-
erate  in driving  tumorigenesis. This 
illustrates  that  meticulous  analysis 
of candidate oncogenes is a neces-
sity  and  also  that  this  can  be  per-
formed  expeditiously  only  with  the 
aid  of mouse models  as  described 




sor  genes,  for  that  matter)  will  be 
located  quite  often  in  close  vicin-evier Inc.ity  to  each  other,  and,  hence,  their 
comutation  by  amplification  (or  by 
deletion  for  tumor  suppressors) 
likely occurs frequently. Thus, a sin-
gle  genetic  aberration  might  affect 
multiple genes, each of which con-
tributes  to  tumorigenesis.  The  Ink4 
locus,  harboring  three  tumor-sup-
pressor genes (p16INK4a, p15INK4b, and 
p14/p19ARF)  in  very  close  proximity, 
is  a  case  in  point,  but  this  is  likely 
true  for  many  other  chromosomal 
regions.
It will  be  important  to  assess  to 
what  extent  the  individual  genes 
described  here  actually  drive  the 
tumorigenic  process.  As  RNAi 
depletion of cIAP1, Yap, or NEDD9 
failed  to  cause  full  tumor  regres-
sion  or  complete  suppression  of 
metastasis,  it  is  unclear  whether 
the corresponding tumors are simi-
larly  “addicted”  to  these  genes  as 
has  been  shown  for  tumor-driv-
ing  mutations  such  as  Bcr-Abl  in 
CML  (chronic  myeloid  leukemia) 
in  humans  and  c-myc  and  H-Ras 
in  several  mouse  tumor  models. 
(Jonkers  and  Berns,  2004;  Wein-
stein,  2002).  In  addition,  it  will  be 
necessary  to  critically  evaluate 
whether concurrent ablation of  the 
coamplified genes can more effec-
tively  contribute  to  tumor  eradica-
tion. The mouse models described 
here  are  exquisitely  suited  to 
address  such  questions,  as  com-
bination  of  different  shRNAs  can 
be used  to genetically ablate gene 
expression  and  assess  the  added 
therapeutic  potential  of  concomi-
tant inhibition of targets. The stud-
ies  described  testify  to  the  notion 
that  genetically  tractable  mouse 
models represent an invaluable tool 
not  only  to  identify  new  cancer-
causing  genes  but  also  to  assess 
the  context-dependent  vulnerabil-
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6, 535–538.Studies  in  vertebrate  cells  have 
shown  that  replication  of  genomic 




lication  sites  were  first  detected  by 
immunostaining  of  newly  replicated 
DNA  or  replication  enzymes  and 
later by monitoring GFP-tagged rep-
lication  factors.  These  approaches 
revealed that replication foci appear 
under  the  microscope  as  spots  of 
varying  size  and  position,  yet  their 
number  per  nucleus  is  far  smaller 
than  the  number  of  genomic  repli-
cation  forks.  Replication  forks were 
thought  to  be  brought  together  by 
a  poorly  characterized  structure 
called  the nuclear matrix  (Tubo and 
Berezney,  1987)  or  by  binding  to 
lamins.  However,  budding  yeast 
does  not  have  a  lamin  protein,  and 
replication  foci  were  nonetheless 
observed  (Lengronne  et  al.,  2001). 
Moreover,  GFP-tagged  replication 
origins  in  yeast  move  constantly  in 
both G1 and S phase cells, rendering 
In and out of t





In this issue of Cell, Kitamura e
vidual genomic loci as they re
to replication factories and sh




















revealed  that  neighboring  replica-
tion  origins  fire  simultaneously  in 




Collectively  these  data  led  to  a 
model  in which  replication  forks are 
brought together at the start of rep-
lication  to  form a  “factory.” Unrepli-
cated DNA would be pulled into this 
factory,  whereas  replicated  sister 
strands  might  be  extruded  (Cook, 
1999)  (Figure  1A).  Unfortunately, 
few  experiments  have  challenged 
this hypothesis directly or  tested  its 





t al. (2006) use live-fluorescenc
plicate in budding yeast. They












events.  In  this  issue, Kitamura et al. 
(2006)  use  budding  yeast  to  char-
acterize  the  nuclear  dynamics  of  a 
single  locus  relative  to  a  replication 
factory.
Budding  yeast  has  well-defined, 
sequence-specific  replication  ori-
gins.  Indeed,  the  timing  of  origin 
firing  and  the  dynamics  of  fork 
progression  have  been  well  char-








by  combining  quantitative  imaging 
of  lacop-  and  tetop-tagged  genomic 
loci  with  an  independent  label  for 
replication  sites.  Amazingly,  using 
deconvolved  images  they  are  able 
to  quantify  the  increase  in  fluores-
cence  that  accompanies  the  dupli-
 factory
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